Monday, November 30, 2020
News
NEWS HOME
»
PRN INDIA
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
  SocialTwist Tell-a-Friend  
   

  • CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside of Greater China
  • Agreement provides a pathway to bring CStone's sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) to global patient communities by partnering with a company with an innovative business model and unique ability to commercialize these two assets competitively against established treatments
  • Terms demonstrate the significant global commercial potential of these two assets and provide immediate cash proceeds to invest in strategic initiatives

SUZHOU, China, Oct. 26, 2020 /PRNewswire/ --  CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively positioned in global markets against established treatments for the target indications.

Under the terms of the agreement, CStone will receive an upfront payment of US$150 million and up to US$1.15 billion in milestone payments for both drugs as well as separate tiered royalties. EQRx will obtain exclusive rights to lead global development and commercialization worldwide, excluding Mainland China, Taiwan, Hong Kong and Macau. CStone retains rights to CS1003 in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug.  

Frank Jiang, M.D., Ph.D., Chairman and Chief Executive Officer of CStone, said: "We are pleased to be partnering with EQRx, an outstanding company led by an exceptional management team with a track record of building and investing in biotech companies as well as leadership roles at commanding heights of the industry. They have a unique blend of expertise to execute on this agreement and maximize the global potential of our two lead immuno-oncology assets. "

"This partnership demonstrates the clinical as well as the commercial potential of sugemalimab and CS1003. Both are well suited to serve as backbone molecules for various combination therapies, an approach that is part of EQRx's vision for these drugs. The broad potential to develop combination therapies further strengthens our ability to pursue our combo strategy for CS1003 in China. In addition, the capital proceeds that we generate through this transaction will enhance our ability to invest in strategic development initiatives and advance our transition into a fully integrated biopharma company."

Alexis Borisy, Chairman, Founder and Chief Executive Officer of EQRx, said: "CStone is recognized globally for excellence in drug development and we look forward to advancing their foundational work to expand access to these two late-stage, innovative immunotherapies. We believe the addition of PD-L1 and PD-1 drug candidates to our expanding clinical pipeline provides EQRx and our strategic partners with optionality to deliver high-quality, lower cost treatment regimens across a broad range of cancers. Ultimately, adding this unique combination of potentially best-in-class immunotherapeutic agents advances our mission to deliver equal access to innovative medicines while lowering costs for patients, payers and healthcare systems around the world."

Sugemalimab is a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including frontline non-small cell lung, gastric and esophageal cancers, among others. The U.S. Food and Drug Administration ("FDA") has recently granted Breakthrough Therapy Designation ("BTD") to this drug for adult relapsed or refractory extranodal natural killer/T-cell lymphoma ("R/R ENKTL"), and orphan drug designation ("ODD") for T-cell lymphoma. CS1003 is currently being studied for the treatment of advanced solid tumors, including a global registration trial in first-line hepatocellular carcinoma. The FDA has granted ODD for this indication.

Closing of the agreement is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Act.

Investor Presentation Information
CStone will host a live webcast at 11:00am (Hong Kong time) October 27th, 2020. Please find the access information as below.

All other regions: https://event.webcasts.com/starthere.jsp?ei=1390413&tp_key=e37a82bd34
Mainland China: https://event.gmwebcasts.cn/starthere.jsp?ei=1390413&tp_key=e37a82bd34
Password (case sensitive): CStone

About Sugemalimab (PD-L1)

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by a company based in the U.S., Ligand Pharmaceuticals Inc. (NASDAQ: LGND), sugemalimab is developed using the OmniRat ® transgenic animal platform, which can generate fully human antibodies in one stop. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 ("IgG4") human antibody, which may reduce the risk of immunogenicity and toxicities in patients, a potentially unique advantage over similar drugs.

Sugemalimab has completed a Phase I dose-escalation study in China. During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.

Currently, sugemalimab is being investigated in a number of ongoing clinical trials. In addition to a Phase I bridging study in the U.S., the clinical programs in China include one multi-arm Phase Ib study for several tumor types, one Phase II registrational study for lymphoma, and four Phase III registrational studies, respectively, for stage III/IV non-small cell lung cancer, gastric cancer, and esophageal cancer. The phase III clinical trial of sugemalimab in patients with stage IV non-small cell lung cancer has reached its primary endpoint. CStone plans to submit a new drug application to the National Medical Products Administration of China soon.

About CS1003 (PD-1)

CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1 (either already approved or in clinical stage), CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2.

About CStone

CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 15 drug candidates, including five late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. For more information about CStone, please visit: www.cstonepharma.com.

About EQRx  

EQRxâ„¢ is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. Headquartered in Cambridge, Massachusetts, the company is backed by GV, ARCH Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32, Nextech, and Arboretum Ventures. For more information, please visit  www.eqrx.com

Forward-looking Statement

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

CSTONE INVESTOR CONTACT
ir@cstonepharma.com

More News by PR Newswire India

BigRock Announces Black Friday Sale with up to 58% OFF on Web Hosting, Domains and more

HostGator India Announces Black Friday & Cyber Monday Discounts on Web Hosting, Domains, Email Hosting and More

Media Alert: Kimpton Maa-Lai Bangkok launches the first in Asia tactile hotel reviews

European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis

Successive Technologies Appraised at CMMI Level 3

Papuan Pastor Questions BBC Reports on Indonesian Palm Oil Company Korindo

Sony Music Brazil launches new programme to boost digital transformation in the Brazilian music industry

'Great Place to Work® India' institute recognizes HashedIn as India's Best Workplaces in IT & IT-BPM 2020

Simplilearn Launches SkillUp Program for Tech Professionals

AstraZeneca's signs MoU with Indian Diabetes Research Society (RSSDI) to empower 1 Crore Indian Diabetic patients by 2023

Xinhua Silk Road: Red Xifeng debuts at NEXT Summit (Sky 2020), spreading Chinese liquor culture through cooperation

Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the third year in a row

Peak performance as Chengdu cleans up with park city vision

ResellerClub offers Black Friday Deals of up to 60% off on Web Hosting & Domains

Tuxera First to Bring Network Bandwidth-Saving SMB Compression Feature to Linux Environments

Autotech Co Hong Kong Limited Completes Two-Year Autonomous Research Project

Eightfold AI Raises $125M Series D Funding Round to Provide the Right Career for Everyone in the World

Statement from XTX Markets: fraudulent company claiming to be affiliated with XTX Markets

Azure Databricks Achieves FedRAMP High Authorization on Microsoft Azure Government (MAG)

Frost & Sullivan Examines 8 Strategic Imperatives for Growth in a Post-COVID World

Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone

5 Ways to Combat Fraud During the Holidays

QS release annual list of Asia's best universities

Home relocation services see more takers in WFH world

Agora Powers Innovative Virtual Experiences Beyond Video Conferencing

Frost & Sullivan Reveals Four Key Areas Driving Growth of the Global Gigabit Ethernet Testing Market

Habanos, S.A. Has Presented the World Premiere Of H. Upmann Connossieur No.2 in Berlin

Virtual Events Platform Airmeet Launches Multi-Track Event Format, Good for Mega-Conferences with Exhibition Booths

GEP Wins Top Honors at Asia Pacific's Prestigious Procurement Success Awards

LONGi supplies 273MW of its solar modules for Southeast Asia's largest solar plant, Phase I of the Xuan Thien Ea Sup Project in Dak Lak, Vietnam

Clarivate Pledges Support for the Women's Empowerment Principles

Managing strategic risk for global companies

SoftIron's Open Source-Based HyperDrive® Storage Solution Verified Veeam Ready

Kavalan Launches Limited Edition 'Artist Series'

Global healthcare experts concerned over rising environmental toxicity and its impact on maternal health in low- and middle-income group countries, including India

The Himalaya Drug Company Introduces Q-DEE Range of Mouth Dissolving Tablets for Immunity and Cramps

Frost & Sullivan awards Digital14 'Company of the Year' in the United Arab Emirates cybersecurity services industry

D-Link Smart Home Products Acquire Taiwan Excellence Award

QAD Adaptive ERP 2020.1 Achieves Veracode Verified Standard Status

Future of digital payments - What's next for India's Digital Space: Lyra Network

Hon'ble Education Minister, Shri Ramesh Pokhriyal 'Nishank' launches various initiatives of Sri Aurobindo Society and HDFC Bank

2020 Global Terrorism Index: Deaths from terrorism reach five-year low, but new risks emerge

Deepak Nitrite ranked and recognized by Forbes Asia as Best Under Billion Top 200

Hiring & Exit Trends Making a Healthy Return to Pre-COVID levels: A data-driven perspective - PeopleStrong

ZTE and GSMA Intelligence Release White Paper on Green 5G - 5G Energy Efficiencies, Green is the New Black

She one of Asia's Top 30 Under 30 and one of Top 30 Women Transforming India. Meet UTS alum Madhavi Shankar.

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

SW China's Chengdu to host event on international supply chain innovation

Cision's New Analytics Dashboards and Interactive Reports Make It Faster and Easier to Demonstrate the Real Business Impact of Earned Media

Adjust Joins Adobe Exchange Partner Program to Enhance App Marketing Measurement, Fraud Prevention and Reporting for Digital Advertisers

Impartner Announces Live 3D Virtual Summit Featuring Top Channel Analysts Jay McBain and Maria Chien

Frost & Sullivan Inspects the Growth Trajectory of Solar PVs Over the Next Decade

ViewSonic Unveils vTouch to Facilitate Multi Touch for macOS

Empire State Realty Trust Achieves GRESB 5 Star Rating in First Year of Participation

Advanced Water Purification Technologies Promise to Deliver Clean and Safe Water to the Global Population

PwC Actuarial Services Hails Aon's PathWise® Platform for IFRS 17 Reporting

STRATACACHE Hires Digital Signage and Retail Veteran to Spearhead Scala Business Development in Canada

The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets

FARO® Launches Latest Vantage Laser Tracker 6DoF Probe

World's Airports And Leading Airlines Join CommonTrust Network And Begin Roll-out Of CommonPass In December In Support Of Safer Border Reopening

Absolut and Beatport Launch NYE 2020 - a 20+ Hour, 15-city, Global New Year's Eve Live Stream Party to #DanceAway2020

Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose

Surge in Global Demand for Personal Mobility Brings New Momentum to Two-wheeler Industry, Says Frost & Sullivan

Frost & Sullivan Presents 5 Technology Growth Opportunities in Sensors and Automation for 2021

Signature Event By Cosmoprof India, A Niche B2B Show For The Beauty Industry, To Be Held On 22-23 February 2021 In Mumbai

Genesys Named a Leader in the Gartner 2020 Magic Quadrant for Contact Center as a Service

ANMI kickstarts 'Investor Awareness Week-2020' under the aegis of SEBI

XCMG launches X-GSS at Bauma China 2020, shows how to go digital in machinery manufacturing

Teachings of Guru Nanak are timeless and are more relevant in today's scenario says spiritual guru Sri Sri Ravi Shankar

Freelance on Demand: Rozgaar India to help Businesses adjust to changing times

SHIELD Announces DeviceSHIELD to Protect Small Businesses from Cyber Fraud During the COVID-19 Pandemic

INSIGHTEC Announces MR-guided Focused Ultrasound to Treat Essential Tremor Received Funding by National Health Service (NHS) England

Smytten - India's largest premium product trial platform, launches their new brand campaign: #BeSomethingNew

Atos awarded with the best CSR project for environment and sustainability in India

Crayon Data's Relevance Quotient Report 2020 Explains the Trends and Patterns of Personalized Banking

Philippines Launches New International Investment Promotion Brand Highlighting Its "Make It Work" Potential

Sinopec kickstarts extensive research on CO2 emissions peak and carbon neutral

HGC honoured with Best OTT Partnership Award

World Leaders and Millions of Citizens Call for Peace at Third Online Rally of Hope

New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials

NPL and Cambridge Quantum Computing (CQC) collaborate in quantum computing

Syngenta Crop Protection announces launch of Spiropidion: a new insecticide active ingredient

Oslo, Los Angeles, Mexico City, Budapest Commit to Clean Construction, Moving the Industry Towards a Sustainable Future

Cobwebs' Threat Intelligence Solutions

American Wave Machines, Inc. Announces Two PerfectSwell® Projects

Yili's dollar bond debut wins the highest international credit rating

Which Windows Internet Security Software protects you best and which slows down your workstation

PR Newswire Publishes 2020 Tech Media Pitching Kit

Singapore-based startup Plano Wins World's Most Innovative HealthTech Startup 2020 Award

Longitude Prize launches AMR Voices: Stories from the frontlines of antibiotic resistance during Covid-19

Clarivate Strengthens IP Offering in Mainland China with New Domain Registrar License

Venture Global LNG Awards KBR EPC Contract for Plaquemines LNG Export Facility

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host virtual international symposium on complex cardiac arrhythmias

Volvo Financial Services Realigns Asia Pacific Organization to Better Serve Customers

Transforming the Future of Digital Health Management - Enjoy a More Fulfilling Life With Zepp

Philip Wong Joins Vasayo as President of Greater China Region

Enterprise Holdings Pledges $120 Million to Advance Social and Racial Equity and Expand the Fight Against Hunger

Tony Blair Institute and Oracle Launch Africa Vaccine Management in the Cloud

GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial

Xinhua Silk Road: Wuliangye joins Chinese business leaders to promote digital productivity in Asia Pacific

Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition

HarperCollins India is delighted to announce the acquisition of two new books by bestselling author, Preeti Shenoy

2020 TADS Awards Winners Announced At "TADS AWARDS GALA 2020" Presentation Ceremony Hosted in Hong Kong

CDNetworks Releases State of the Web Security for H1 2020: Web Application Attacks Boosted Over 800%

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

Zentiva Continues Its Planet-Z Program For A Healthier Planet By Planting 4,500 Trees In Portugal

Frost & Sullivan Recognizes Menlo Security as a Growth and Innovation Leader in the Asia-Pacific Web Security Market

Godrej Interio launches essential range, ushering festivities in India

Zymo Research Receives CE IVD Mark for its Quick-DNA/RNAâ„¢ Viral MagBead Kit

Indira IVF is now in 93 centres across India

Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies

GCash overtakes popular brands in local app rankings

G20 Riyadh Summit: Release of Leaders' Declaration

CGTN: China calls for more inclusive development in post-COVID world

Family Photo from Today's Opening Session of the G20 Riyadh Summit

OPENING REMARKS: G20 Riyadh Summit

GAC MOTOR Lands in Chile With Its GS4, GS3, and GA4, building up strength in South America and Accelerating Global Expansion

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Shah positive about resumption of mining...
7 alleged Maoists surrender before polic...
Our goal is to establish Gandhi's Ram Ra...
Educational institutions to remain close...
Cartel TikTok: Narcos post guns, drugs a...
Man held for shooting friend in Gurugram...
More...    
 
 Top Stories
Need to work on rotating the strike... 
Goa looking for first win of the se... 
PM to interact with more teams of C... 
Shah positive about resumption of m... 
Khattar could have called me up on ... 
Odisha Assembly adjourned sine die ... 
Team breathed a sigh of relief afte... 
Rohit Saraf: Look forward to everyt...